[1]何丽,苏进,钱英净,等.放化疗联合区域热疗治疗老年宫颈癌患者有效性及安全性分析[J].中国医学物理学杂志,2026,43(6):727-731.[doi:DOI:10.3969/j.issn.1005-202X.2026.06.004]
　HE Li,SU Jin,QIAN Yingjing,et al.Efficacy and safety of chemoradiotherapy combined with regional hyperthermia for elderly patients with cervical cancer[J].Chinese Journal of Medical Physics,2026,43(6):727-731.[doi:DOI:10.3969/j.issn.1005-202X.2026.06.004]
点击复制

放化疗联合区域热疗治疗老年宫颈癌患者有效性及安全性分析()

《中国医学物理学杂志》[ISSN:1005-202X/CN:44-1351/R]

卷:
43卷
期数:
2026年第6期
页码:
727-731
栏目:
医学放射物理
出版日期:
2026-06-26

文章信息/Info

Title:
Efficacy and safety of chemoradiotherapy combined with regional hyperthermia for elderly patients with cervical cancer
文章编号:
1005-202X（2026）06-0727-05
作者:
何丽; 苏进; 钱英净; 刘燕; 颜清; 高莹
西安交通大学第一附属医院肿瘤放疗科， 陕西 西安 710061
Author(s):
HE Li;  SU Jin;  QIAN Yingjing;  LIU Yan;  YAN Qing;  GAO Ying
Department of Radiotherapy, the First Affiliated Hospital of Xian Jiaotong University, Xian 710061, China
关键词:
宫颈癌; 老年患者; 放化疗; 区域热疗; 安全性
Keywords:
Keywords: cervical cancer elderly patient chemoradiotherapy regional hyperthermia safety
分类号:
R319；R737.33；R816.93
DOI:
DOI:10.3969/j.issn.1005-202X.2026.06.004
文献标志码:
A
摘要:
目的：探讨老年宫颈癌患者使用放化疗联合区域热疗治疗的效果和安全性。方法：选取2018年2月至2021年2月在西安交通大学第一附属医院就诊治疗的154例老年宫颈癌患者，根据患者选择治疗方法分为联合治疗组（n=77，放化疗联合区域热疗）和放化疗治疗组（n=77，放化疗治疗）。比较两组患者的近期治疗情况（肿瘤缓解率）、血清肿瘤标志物水平［癌胚抗原（CEA)、恶性肿瘤特异生长因子（SCC）、糖抗原125（CA125）］、疼痛缓解率、不良反应发生情况和远期治疗效果。结果：联合治疗组近期肿瘤缓解率高于放化疗治疗组（P<0.05）；治疗后联合治疗组CEA、SCC和CA125水平均低于放化疗治疗组（P<0.05）；联合治疗组疼痛缓解率高于放化疗治疗组［86.54%（45/52） vs 60.00%（30/50）, [χ2]=9.224, P=0.002）；联合治疗组与放化疗治疗组不良反应发生无显著差异（P>0.05）；联合治疗组无进展生存期（PFS）为6~36月，无进展生存率为23.38%，放化疗治疗组PFS为7~36月，无进展生存率为10.39%，Kaplan-Meier生存分析，两组患者的无进展生存分布差异有统计学意义（Log-rank检验[χ2]=13.512, P<0.001）；联合治疗组总生存期（OS）为6~36月，总生存率为49.35%，放化疗治疗组OS为7~36月，总生存率为25.97%。Kaplan-Meier生存分析显示两组患者的生存期分布差异有统计学意义（Log-rank检验[χ2]=21.541, P<0.001）。结论：老年宫颈癌患者使用放化疗联合区域热疗可有效提升肿瘤治疗效果，降低CEA、SCC、CA125等血清肿瘤标志物水平，缓解患者疼痛情况，提升患者PFS和OS。 【关键词】宫颈癌；老年患者；放化疗；区域热疗；安全性
Abstract:
Abstract: Objective To investigate the efficacy and safety of chemoradiotherapy combined with regional hyperthermia in the treatment of elderly patients with cervical cancer. Methods A total of 154 elderly patients with cervical cancer treated at the First Affiliated Hospital of Xian Jiaotong University between February 2018 and February 2021 were enrolled and divided into a combination group (n=77, chemoradiotherapy combined with regional hyperthermia) and a chemoradiotherapy group (n=77, chemoradiotherapy). Short-term therapeutic efficacy (tumor remission rate), serum tumor markers (CEA, SCC, CA125), pain relief rate, incidence of adverse events, and long-term therapeutic outcomes were compared between the two groups. Results Compared with the chemoradiotherapy group, the combination group had a higher tumor remission rate (P<0.05), lower post-treatment serum CEA, SCC, and CA125 levels (P<0.05), and a higher pain relief rate [86.54% (45/52) vs 60.00% (30/50), [χ2]=9.224, P=0.002]. No significant differences were observed in the adverse events between the two groups (P>0.05). The progression-free survival (PFS) of the combination group ranged from 6 to 36 months, with a PFS rate of 23.38%, whereas the PFS of the chemoradiotherapy group was 7 to 36 months, with a PFS rate of 10.39%. Kaplan-Meier survival analysis revealed a statistically significant difference in PFS between the two groups (Log-rank test [χ2]=13.512, P<0.001). The overall survival (OS) of the combination group was 6 to 36 months, with an OS rate of 49.35%, whereas the OS of the chemoradiotherapy group was 7 to 36 months, with an OS rate of 25.97%. Kaplan-Meier survival analysis demonstrated a statistically significant difference in OS between the two groups (Log-rank test [χ2]=21.541, P<0.001). Conclusion The application of chemoradiotherapy combined with regional hyperthermia in elderly patients with cervical cancer can effectively enhance anti-tumor efficacy, reduce serum levels of tumor markers such as CEA, SCC and CA125, relieve the pain, and prolong PFS and OS.

相似文献/References:

[1]戴相昆,杨丰蔚,杜 镭,等.等效均匀剂量优化法在宫颈癌调强计划中的应用[J].中国医学物理学杂志,2015,32(02):290.[doi:10.3969/j.issn.1005-202X.2015.02.033]
[2]刘 浩,王 新,李公平,等.宫颈癌放疗高危临床靶区变化及其对累计吸收剂量的影响[J].中国医学物理学杂志,2015,32(03):379.[doi:10.3969/j.issn.1005-202X.2015.03.017]
[3]孙晓欢,周咏春,谭丽娜,等.容积旋转调强与固定野调强在宫颈癌术后放疗中的剂量学比较[J].中国医学物理学杂志,2014,31(01):4604.[doi:10.3969/j.issn.1005-202X.2014.01.003]
[4]刘 浩,王 新,李公平,等.用二维电离室矩阵验证宫颈癌腔内放疗剂量分布[J].中国医学物理学杂志,2014,31(04):4988.[doi:10.3969/j.issn.1005-202X.2014.04.004]
[5]余 辉,张书旭.宫颈癌后装治疗剂量的调强优化方法[J].中国医学物理学杂志,2014,31(05):5114.[doi:10.3969/j.issn.1005-202X.2014.05.004]
[6]查元梓,张松方,屠永清,等.子野权重优化对CMS XiO宫颈癌调强计划的影响[J].中国医学物理学杂志,2013,30(01):3866.[doi:10.3969/j.issn.1005-202X.2013.01.007]
[7]张富利,刘清智,张伟超,等.宫颈癌术后盆腔螺旋断层调强放疗两种计划设计方法的剂量学分析[J].中国医学物理学杂志,2013,30(04):4229.[doi:10.3969/j.issn.1005-202X.2013.04.003]
[8]王佳浩,赖建军,唐荣军,等.结合EPID与EUD方法确定宫颈癌病例靶区最佳生物外放边界的研究[J].中国医学物理学杂志,2013,30(05):4378.[doi:10.3969/j.issn.1005-202X.2013.05.009]
[9]张富利,刘清智,王雅棣,等.基于配置不同类型MLC叶片加速器的宫颈癌术后调强放疗计划评估[J].中国医学物理学杂志,2013,30(05):4383.[doi:10.3969/j.issn.1005-202X.2013.05.010]
[10]刘致滨,王占宇,龙雨松.两种优化技术在宫颈癌术后IMRT计划中的比较[J].中国医学物理学杂志,2015,32(04):534.[doi:10.3969/j.issn.1005-202X.2015.04.018]
　[J].Chinese Journal of Medical Physics,2015,32(6):534.[doi:10.3969/j.issn.1005-202X.2015.04.018]

备注/Memo

备注/Memo:
【收稿日期】2025-12-05 【基金项目】陕西省科技计划项目（2025JC-YBMS-1065） 【作者简介】何丽，主管护师，研究方向：肿瘤放射治疗的护理，E-mail: hldyx228@163.com 【通信作者】高莹，博士，副主任医师，研究方向：肿瘤放射治疗，E-mail: togaoying@163.com
更新日期/Last Update: 2026-06-26